Life Science Giant Danaher's Q2 Earnings Beat Estimates On 'Sustained Positive Momentum In Bioprocessing Business', Maintains Guidance
Life Science Giant Danaher's Q2 Earnings Beat Estimates On 'Sustained Positive Momentum In Bioprocessing Business', Maintains Guidance
On Tuesday, Danaher Corp's (NYSE:DHR) second quarter sales decreased 3% year-over-year to $$5.743 billion, beating the consensus of $5.59 billion.
週二，丹納赫公司（紐約證券交易所代碼：DHR）第二季度銷售額同比下降3％，至57.43億美元，超過市場預期的55.9億美元。
Non-GAAP core revenue decreased by 3.5%, compared to the expectations of a decline in the mid-single digits.
非公認會計准則核心收入下降了3.5％，而預期的下降幅度爲中等個位數。
Danaher reported second-quarter adjusted EPS of $1.72, beating the consensus of $1.57.
丹納赫公佈的第二季度調整後每股收益爲1.72美元，高於市場普遍的1.57美元。
Operating cash flow was $1.4 billion, and non-GAAP free cash flow was $1.1 billion.
運營現金流爲14億美元，非公認會計准則自由現金流爲11億美元。
Rainer M. Blair, President and Chief Executive Officer, stated, "We were particularly pleased with the sustained positive momentum in our bioprocessing business and with strong performance at Cepheid, which we believe gained market share in molecular testing again this quarter."
總裁兼首席執行官雷納·布萊爾表示：“我們對生物加工業務的持續積極勢頭以及Cepheid的強勁表現感到特別滿意，我們認爲Cepheid在本季度再次增加了分子測試的市場份額。”
Also Read: Danaher's Spun-Off Company Veralto Is "Next High-Quality Serial Compounder" – Analyst.
另請閱讀：丹納赫的分拆公司Veralto是 “下一個高質量的串行復合生產商” ——分析師。
Biotechnology sales fell 9% from $1.86 billion to $1.71 billion. Life Sciences segment sales decreased slightly from $1.79 billion to $1.77 billion. Diagnostic sales increased from $2.23 billion to $2.26 billion.
生物技術銷售額下降了9％，從18.6億美元降至17.1億美元。生命科學板塊的銷售額從17.9億美元略有下降至17.7億美元。診斷銷售額從22.3億美元增加到22.6億美元。
The operating margin of 27.3% came in above the guidance of around 26%.
27.3％的營業利潤率高於約26％的預期。
Guidance: Danaher expects the fiscal year 2024 non-GAAP core revenue to be down low-single digits year-over-year.
指導方針：丹納赫預計，2024財年的非公認會計准則核心收入將同比下降個位數。
For the third quarter of 2024, Danaher anticipates non-GAAP core revenue will be down in the low-single digits year-over-year.
丹納赫預計，2024年第三季度的非公認會計准則核心收入將同比下降至較低的個位數。
The company forecasts a third-quarter adjusted operating margin of around 26% and reaffirms fiscal year 2024 margin guidance of ~29%.
該公司預測第三季度調整後的營業利潤率約爲26％，並重申2024財年的利潤率約爲29％。
The company forecasts that 2024 bioprocessing core revenue will decline in the low single digits, and Cepheid 2024 respiratory revenues will be around $1.6 billion.
該公司預測，2024年生物處理核心收入將下降至較低的個位數，而Cepheid 2024呼吸收入將約爲16億美元。
Price Action: At the last check on Tuesday, DHR stock was up 7.20% at $268.96.
價格走勢：在週二的最後一次檢查中，DHR股價上漲7.20％，至268.96美元。
- EXCLUSIVE: Adial Pharmaceuticals Moves Forward To Second Cohort In Pharmacokinetics Study of AD04 For Alcohol Use Disorder.
- 獨家：Adial Pharmicals進入第二組AD04酒精使用障礙的藥代動力學研究。
Photo via Company
照片來自公司